Infinity Pharmaceuticals has gained access to Intellikine's portfolio of phosphoinositide 3-kinase-δ (PI3Kδ) and PI3Kγ inhibitors for inflammation and oncology indications through an exclusive ...

The FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi) for use in combination with palbociclib (Ibrance) and ...

The US Food and Drug Administration (FDA) has approved Roche’s Itovebi (inavolisib) in combination with Pfizer’s Ibrance ...